Melanoma physician-scientist @DanaFarber Asst Prof @harvardmed. Graduate @OslerResidency @UofTMDprogram. views are my own.
Boston, MA
Joined January 2012
- Tweets100
- Following350
- Followers376
- Likes176
Pinned Tweet
We're hiring post-docs and research technicians! Contact me if you're interested in joining our team.
Riz Haq MD PhD retweeted
New research published in Proceedings of the National Academy of Sciences by @DanaFarber’s Rizwan Haq, MD, PhD, identifies a regulator that recruits active Gα proteins to the endolysosomal compartment via an evolutionarily conserved motif shared across multiple Gα proteins. These findings define a spatial vulnerability with broad therapeutic relevance for diseases driven by dysregulated G-protein signaling, including the vast majority of uveal melanomas. Read more here: bit.ly/3Th2JJW
1/2 Thrilled to report our latest study, published now at PNAS: pnas.org/doi/10.1073/pnas.26…. In this study, we find that GPCR signaling isn't just a plasma-membrane event — active Gα proteins get shuttled to the endolysosomal compartment by AP-3, using an ancient conserved motif.
2/2 Blocking this trafficking halts tumor growth & metastasis in uveal melanoma, where oncogenic Gα mutations drive disease. A new "spatial vulnerability" in G-protein signaling. Thanks to our collaborators Mikel Garcia-Marcos and @kaelin_lab.
Thank you to the Isaacson's for the generous support of this ocular melanoma fellowship! danafarberimpact.org/2025/06…
We’re hiring post-docs! Join our lab on projects involving immunotherapy and therapy resistance and metastasis in cutaneous and uveal melanoma. Please DM if interested!
5/The project was only possible because of collaboration with the Van Allen lab, talented co-first authors Julia Schiantarelli, Mouadh Benamar, Jihye Park. I am also grateful to patients who donated biopsy material and funding sources, including @MelanomaReAlli @DanaFarberNews
3/Strikingly, we found resistance-associated mutations in SEC24C and SEC24D in 3 patients. Melanoma cells engineered to express the SEC24C mutations observed in patients exhibit diminished STING signaling, including decreased Type I interferon production, antigen presentation
2/Over several years, we collected matched pre-treatment and post-resistance tumor biopsies in patients with metastatic melanoma who exhibited heterogeneous ICI responses to nominate additional mediators of acquired resistance.
1/Although some patients with metastatic melanoma experience durable responses to immune checkpoint inhibitors, most exhibit intrinsic or acquired resistance to these therapies.
Our paper on a new mechanism of resistance to immunotherapy in melanoma is now in print @Cancer_Cell with the Van Allen lab @VanAllenLab
cell.com/cancer-cell/fulltex…
Details of the paper below
Riz Haq MD PhD retweeted
Now online in @CD_AACR: A Next-Gen #BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients w/BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation - by @RonaYaeger, S. Michael Rothenberg, et al. doi.org/10.1158/2159-8290.CD… @MSKCancerCenter @PfizerOncMed
Riz Haq MD PhD retweeted
For #ScienceSunday, Dr. Haq from @DanaFarber & one of the recipients of our inaugural Options Bring Hope Team award, speaks with our attendees about his award winning research titled “Identification of Molecular pathways that drive uveal melanoma Metastasis.” #EyeGetDilated #OM
Hope you can join us. Should be a great event for uveal melanoma patients and their families/caregivers. xitter.gq/MRFCureOM/status/17734…
A special thank you to our partners,@DanaFarber, @MassEyeAndEar, @MassGeneralNews & @TuftsMedicalCtr for collaborating w/ us for this year’s event. Register today so that you can join us for informative sessions around #OM treatment, diagnosis & more -buff.ly/42Zb063
Riz Haq MD PhD retweeted
In the May issue of Cancer Discovery, Adapted to survive: targeting cancer cells with BH3 mimetics by @JoanMonte and @rhaq1.
bit.ly/3N6GYUw
@DanaFarber @harvardmed @IBECBarcelona
We argue that pre-treatment markers do not predict responses to these agents, but adaptive responses must be recognized and targeted to achieve meaningful responses to BH3 mimetics. Thanks to @MelanomaReAlli for their support.
Thrilled to share our review in @CD_AACR with @JoanMonte which discusses anti-apoptosis inhibitors (BH3 mimetics) in cancer. aacrjournals.org/cancerdisco…
Riz Haq MD PhD retweeted
New @DanaFarber Division of Cancer Genetics and Prevention positions for two medical geneticists or medical oncologists! Info below, please share:
careercenter.asco.org/job/76…
Great news!!
We are proud to be able to announce that our TCR therapy has been formally approved by the @US_FDA Full announcement: ir.immunocore.com/news-relea…
